CALPORTA THERAPEUTICS
Calporta is developing selective small molecule agonists of TRPML1 (transient receptor potential cation channel, mucolipin subfamily, member 1) for the treatment of Niemann-Pick C Disease (NPC) and other lysosomal storage diseases. Mutations that cause NPC lead to impaired intracellular lipid trafficking and lead to lysosomal accumulation of cholesterol and biolipds. TRPML1 is an ion channel in the lysosome and a key regulator of lysosomal trafficking processes. Impaired TRPML1 function has been... implicated in multiple pathological conditions, including NPC. Agonists of TRPML1 restore calcium efflux and normalize lysosomal trafficking and function. In addition to NPC and other lysosomal storage diseases, agonists of TRPML1 may have broad potential in other diseases such as muscular dystrophy and various taopathies such as Alzheimer's disease. Calporta's approach is based on research from the lab of Haoxing Xu, Ph.D., at the University of Michigan.
CALPORTA THERAPEUTICS
Industry:
Health Care Medical Therapeutics
Founded:
2015-01-01
Address:
La Jolla, California, United States
Country:
United States
Total Employee:
1+
Status:
Active
Total Funding:
10 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail IPv6 Google Google Cloud DigiCert SSL Pound Sterling Microsoft Japanese Yen
Similar Organizations
Calimmune
Calimmune is a clinical-stage gene therapy company.
Chimeron Bio
Chimeron Bio develops agents for personalized cancer gene therapy.
Scholar Rock
Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.
Viking Therapeutics
Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders.
Current Employees Featured
Investors List
Avalon Ventures
Avalon Ventures investment in Series A - Calporta Therapeutics
GSK
GSK investment in Series A - Calporta Therapeutics